Search company, investor...

Flexible Stenting Solutions

flexiblestent.com

Founded Year

2006

Stage

Acquired | Acquired

Total Raised

$6M

About Flexible Stenting Solutions

Flexible Stenting Solutions is a developer of peripheral arterial stents has submitted an Investigational Device Exemption (IDE) application to the FDA for its FlexStent Femoropopliteal SE Stent System. The FlexStent System is designed to optimize flexibility, fracture resistance and radial strength with predictable placement.

Headquarters Location

23 Christopher Way Suite 103

Eatontown, New Jersey, 07724,

United States

732-578-0060

Missing: Flexible Stenting Solutions's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Flexible Stenting Solutions's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Flexible Stenting Solutions Patents

Flexible Stenting Solutions has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/28/2015

7/3/2018

Implants (medicine), Arteries of the lower limb, Vascular diseases, Drug delivery devices, Dosage forms

Grant

Application Date

8/28/2015

Grant Date

7/3/2018

Title

Related Topics

Implants (medicine), Arteries of the lower limb, Vascular diseases, Drug delivery devices, Dosage forms

Status

Grant

Latest Flexible Stenting Solutions News

Cordis Acquires Flexible Stenting Solutions, a Burrill Capital Fund IV Portfolio Company

Mar 19, 2013

SAN FRANCISCO, CA--(Marketwire - Mar 19, 2013) - Cordis Corporation, a worldwide leader in the development of interventional vascular technology, said it has completed the acquisition of Flexible Stenting Solutions, Inc., a leading developer of innovative flexible peripheral arterial, venous, and biliary stents. Currently, Cordis markets the S.M.A.R.T. Vascular Stent worldwide. The company said the addition of Flexible Stenting Solutions' FlexStent Self Expanding Stent System provides Cordis with the opportunity to evolve the S.M.A.R.T. Stent platform to address unmet needs in the treatment of peripheral artery disease. It also extends the company's opportunity to expand therapeutic applications into below-the-knee and venous interventions. An estimated 27 million people in Europe and North America alone suffer from peripheral artery disease, which is caused by the build-up of fatty substances that collect and adhere to the linings of arteries. David Wetherell, President of Burrill Healthcare Investment Funds, and Joshua Zelig, director of Burrill & Company, both served as directors on Flexible Stenting Solution's board. Terms of the acquisition were not disclosed. "This acquisition represents a great fit for Cordis and FlexStent," said Wetherell. "This should help extend the reach of FlexStent's technology to patients with peripheral artery disease, as well as to others who can benefit from superior peripheral stenting. We are pleased, as well, to provide our investors with a healthy positive return less than 15 months from the effective date of the investment. " About Burrill & Company Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With $1.5 billion in assets under management, the firm's businesses include venture capital/private equity, merchant banking, and media. By leveraging the scientific and business networks of its team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, transactional support, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia. For more information visit: www.burrillandco.com . Contact Information

Flexible Stenting Solutions Frequently Asked Questions (FAQ)

  • When was Flexible Stenting Solutions founded?

    Flexible Stenting Solutions was founded in 2006.

  • Where is Flexible Stenting Solutions's headquarters?

    Flexible Stenting Solutions's headquarters is located at 23 Christopher Way, Eatontown.

  • What is Flexible Stenting Solutions's latest funding round?

    Flexible Stenting Solutions's latest funding round is Acquired.

  • How much did Flexible Stenting Solutions raise?

    Flexible Stenting Solutions raised a total of $6M.

  • Who are the investors of Flexible Stenting Solutions?

    Investors of Flexible Stenting Solutions include Cordis, Biomark Capital and Goodman Co..

  • Who are Flexible Stenting Solutions's competitors?

    Competitors of Flexible Stenting Solutions include Itamar Medical, Endologix, ArraVasc, Tryton Medical, IDev Technologies and 10 more.

Compare Flexible Stenting Solutions to Competitors

M
Micell Technologies

Micell Technologies aims to bring together the clinical advantages of a drug-eluting stent with the long-term safety and stability of a bare metal stent.

T
TriReme Medical

TriReme Medical is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The company is focused on the US and the emerging Asian markets.

S
SquareOne

SquareOne is developing a stent delivery system.

Tryton Medical Logo
Tryton Medical

Tryton Medical is a developer of stent systems for the treatment of bifurcation lesions. The Tryton Side Branch Stent System is built for bifurcation using Tri-ZONE technology to offer a dedicated strategy for treating bifurcation lesions. Tryton's cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel. The stent system has received CE Mark and is commercially available throughout Europe, Russia and the Middle East. It is approved in the United States for investigational use only.

S
Svelte Medical Systems

Svelte Medical Systems is engaged in the development of highly deliverable balloon expandable stents. The Svelte IDS is designed to realize the clinical, time and cost-savings benefits of direct stenting in a single platform. Svelte is developing a Sirolimus eluting stent that has non-inflammatory properties, potentially making it less irritating to the vessel lining than stents with typical polymeric coatings. The Svelte DES is being developed to have the same drug release kinetics as the market leaders while potentially minimizing inflammation in the vessel to reduce the need for long term dual anti-platelet therapy.

Endologix Logo
Endologix

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.